Ocugen Inc OCGN

NAS: OCGN | ISIN: US67577C1053   30/04/2025
0,747 USD (+2,65%)
(+2,65%)   30/04/2025
Grafiek Ocugen Inc Grafiek Ocugen Inc

Ocugen Inc in het nieuws

8 juni 2024 · OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit · Persbericht

6 juni 2024 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen · Persbericht

31 mei 2024 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen · Persbericht

24 mei 2024 · OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit · Persbericht

25 september 2021 · OCUGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN · Persbericht

13 augustus 2021 · DEADLINE NEXT TUESDAY: Shareholders with Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN · Persbericht

4 augustus 2021 · SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN · Persbericht

29 juli 2021 · SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN · Persbericht

17 juli 2021 · Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. and Certain Officers - OCGN · Persbericht

13 juli 2021 · OCUGEN INVESTOR NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN · Persbericht

Profiel Ocugen Inc

Biotechnologie
Farmaceutica
Gezondheidstechnologie
Productie
Productie van sanitaire papierwaren

Website: www.histogenics.com

Hoofdzetel: Malvern, Pennsylvania vlag Verenigde Staten

CEO: Shankar Musunuri

Werknemers: 96

Mijn selecties